PUBLISHER: DelveInsight | PRODUCT CODE: 1544160
PUBLISHER: DelveInsight | PRODUCT CODE: 1544160
DelveInsight's "Atherosclerotic Cardiovascular Disease (ASCVD) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the ASCVD, historical and forecasted epidemiology and the Atherosclerotic Cardiovascular Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Atherosclerotic Cardiovascular Disease market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Atherosclerotic Cardiovascular Disease market size from 2020 to 2034. The report also covers current Atherosclerotic Cardiovascular Disease treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2020-2034
Atherosclerotic Cardiovascular Disease (ASCVD) Overview
ASCVD is a progressive and chronic condition that can affect various arteries throughout the body, including those supplying the heart (coronary arteries), brain (cerebral arteries), and legs (peripheral arteries). The most common manifestations of ASCVD include coronary artery disease (CAD), cerebrovascular disease (stroke), and peripheral arterial disease (PAD).
The development of ASCVD is influenced by a number of risk factors, such as poor diet, inactivity, cigarette use, obesity, family history, and alcohol abuse. The early stages of ASCVD are without symptoms, but later on as the artery narrows and blood flow is reduced, symptoms start to show. The type of artery that is affected and how much blood flow is impeded may also alter the symptoms. Angina, cold chills, dizziness, acute exhaustion, shortness of breath, and heart palpitations are a few typical symptoms.
Atherosclerotic Cardiovascular Disease (ASCVD) Diagnosis
In addition to symptoms, risk assessment is also used to make the diagnosis of ASCVD. Apolipoprotein E [APOE], LDLR, APOB, PCSK9, or LDLRAP1 genes; genotyping to study variations in contributing genes; and morphological examinations (ultrasonography, computed tomography, magnetic resonance imaging/angiography, or catheterization) are typically used to make a clinical diagnosis of ASCVD. Genetic testing, biomarker testing, and imaging can all be used to confirm an ASCVD diagnosis if a doctor has a suspicion. However, the cost and accessibility of genetic testing and biomarker testing may restrict their use.
Further details related to country-based variations are provided in the report
Atherosclerotic Cardiovascular Disease (ASCVD) Treatment
Treatment strategies for Atherosclerotic Cardiovascular Disease occur at the population level but also engage individual adults to slow the development of ASCVD. Promoting a healthy lifestyle throughout life is the most important way to prevent ASCVD. Treatment other than lifestyle modification is based on pharmacotherapy and invasive procedures. A comprehensive patient-centered approach that addresses all aspects of a patient's lifestyle habits and estimated risk of a future ASCVD event is the first step in deciding where there may be a need for pharmacotherapy. For clinical ASCVD, revascularization procedures such as angioplasties and bypass are warranted, among others.
As the market is derived using the patient-based model, the Atherosclerotic Cardiovascular Disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease, (ASCVD), Gender-specific Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease (ASCVD), Age-specific Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease (ASCVD) and Comordidity-specific Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease (ASCVD) in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034. As per DelveInsight's estimations, the total diagnosed prevalent cases of Atherosclerotic Cardiovascular Disease in the 7MM was approximately 55 million cases in 2022 and are projected to increase during the forecast period.
The drug chapter segment of the Atherosclerotic Cardiovascular Disease report encloses a detailed analysis of Atherosclerotic Cardiovascular Disease marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands Atherosclerotic Cardiovascular Disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Marketed Drugs
LEQVIO (Inclisiran): Novartis Pharmaceuticals Corporation
LEQVIO (Inclisiran) is a sole small-interfering RNA (siRNA) therapy designed to lower LDL cholesterol. The drug utilizes the RNA interference mechanism and directs the catalytic breakdown of mRNA for PCSK9. This increases LDL-C receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and lowers LDL-C levels in the circulation.
Emerging Drugs
Olpasiran (AMG 890): Amgen Inc.
Olpasiran (formerly AMG 890) is a small interfering RNA (siRNA) that lowers lipoprotein(a), also known as Lp(a). It is being investigated for treating ASCVD; the drug is administered subcutaneously as a solution. Currently, the company is recruiting for Phase III clinical trial to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with ASCVD and elevated lipoprotein (a).
Obicetrapib (TA-8995): NewAmsterdam Pharma
Obicetrapib is a novel, selective CETP inhibitor that potently decreases low-density lipoprotein-cholesterol (LDL-C) as well as increases high-density lipoprotein-cholesterol (HDL-C) and the number of ApoA1-containing lipoproteins. The drug candidate is designed to be administered orally. Currently, the company is recruiting for Phase III clinical trials to evaluate the effect of obicetrapib on the risk of major adverse cardiovascular events (MACE), including cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke, or non-elective coronary revascularization.
Atherosclerotic Cardiovascular Disease has a diverse treatment classification associated with the disease landscape. ASCVD treatment aims to mitigate cardiovascular risk factors through lifestyle modifications, pharmacological interventions, and invasive procedures as needed.
Statins and PCSK9 inhibitors are major revenue generators in the current treatment landscape. The use of statins and PCSK9 inhibitors is guided by clinical practice guidelines, which provide evidence-based recommendations to healthcare professionals to manage ASCVD.
The market for Atherosclerotic Cardiovascular Disease is expected to experience positive growth with the approval of potential drugs like MK-0616, Obicetrapib (TA-8995), and TQJ230 (pelacarsen).
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, Obicetrapib (TA-8995) in the US is expected to have medium drug uptake with a probability-adjusted peak share of around 1%, and years to the peak is expected to be 7 years from the year of launch.
Further detailed analysis of emerging therapies drug uptake in the report...
Atherosclerotic Cardiovascular Disease (ASCVD) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Atherosclerotic Cardiovascular Disease emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Atherosclerotic Cardiovascular Disease evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Rollins School of Public Health, Emory University, Atlanta, Georgia; Department of Epidemiology and Health Monitoring, Robert Koch Institute; Cardiovascular Prevention Institute, Paris; Teikyo Academic Research Center, Teikyo University, Itabashi-ku, Tokyo, and others.
Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Atherosclerotic Cardiovascular Disease market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Market Insights
Epidemiology Insights
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
8.6.. Japan